Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatelizumab in Relapsing-Remitting Multiple Sclerosis
NCT02222948Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of vatelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Started Sep 2014; status: terminated.
02
Drugs
vatelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02222948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222948.